A blood-based algorithm for the detection of Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 32, Issue 1, 2011, Pages 55-62

  O'Bryant, Sid E ^a,g   Xiao, Guanghua ^b   Barber, Robert ^d   Reisch, Joan ^b   Hall, James ^d   Cullum, C Munro ^b,c   Doody, Rachelle ^e   Fairchild, Thomas ^d   Adams, Perrie ^b   Wilhelmsen, Kirk ^f   Diaz Arrastia, Ramon ^c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f South Carolina Division   (United States)

^g TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Algorithm, blood based; Alzheimer's disease; Diagnosis

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA 2 MACROGLOBULIN; ANGIOPOIETIN 2; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CREATINE KINASE MB; EOTAXIN 3; FAS ANTIBODY; FAS LIGAND; FERRITIN; FIBRINOGEN; INTERLEUKIN 10; INTERLEUKIN 5; INTERLEUKIN 7; LIPOPROTEIN A; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PANCREAS POLYPEPTIDE; PLASMA PROTEIN; STEM CELL FACTOR; TENASCIN; THROMBOPOIETIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

30 PROTEIN RISK SCORE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALGORITHMS; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; AREA UNDER CURVE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; EDUCATIONAL STATUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; MALE; NERVE TISSUE PROTEINS; NEUROPSYCHOLOGICAL TESTS; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 80051941304     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000330750     Document Type: Article

References (41)

1. Alzheimer's Association: 2008 Alzheimer's disease facts and figures. Alzheimers Dement 2008;4:110-133.
2. O'Bryant S, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R, Texas Alzheimer's Research Consortium: A serum protein-based algorithm for the detection of Alzheimer's disease. Arch Neurol 2010;67:1077-1081.
3. Schneider P, Hampel H, Buerger K: Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther 2009;15:358-374.
4. Thal LJ, et al: The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:6-15. (Pubitemid 44356888)
5. Ray S, et al: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007;13:1359-1362. (Pubitemid 350073592)
6. Booij BB, et al: A gene expression pattern in blood for the early detection of Alzheimer's disease. J Alzheimers Dis 2011;23:109-119.
7. Rye PD, et al: A novel blood test for the early detection of Alzheimer's disease. J Alzheimers Dis 2011;23:121-129.
8. O'Bryant SE, et al: A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 2010;67:1077-1081.
9. Mueller SG, et al: Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 2005;1:55-66. (Pubitemid 43348857)
10. Waring S, O'Bryant SE, Reisch JS, Diaz-Arrastia R, Knebl J, Doody R, Texas Alzheimer's Research Consortium: The Texas Alzheimer's Research Consortium longitudinal research cohort: Study design and baseline characteristics. Texas Pub Health J 2008;60:9-13.
11. O'Bryant SE, et al: Brain-derived neurotrophic factor levels in Alzheimer's disease. J Alzheimers Dis 2009;17:337-341.
12. McKhann D, Drockman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group. Neurology 1984;34:939-944.
13. Wechsler D: Wechsler Memory Scale, ed 3. San Antonio, The Psychological Corporation, 1997.
14. Lezak MD, Howieson DB, Loring DW: Neuropsychological Assessment, ed 4. Oxford, Oxford University Press, 2004.
15. Strauss E, Sherman E M S, Spreen O: A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, ed 3. Oxford, Oxford University Press, 2006.
16. Yesavage JA, Brink TL, Rose TL, et al: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983;17:37-49. (Pubitemid 13123113)
17. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
18. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules (see comment). Neurology 1993;43:2412-2414. (Pubitemid 23346995)
19. Ivnik R, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, Kurkland LT: Mayo's Older Americans Normative Studies: WAIS-R norms for age 56 to 97. Clin Neuropsychol 1992;6:1-30.
20. Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC: Neuropsychological tests' norms above age 55 COWAT, BNT, MAE Token, WRAT-R Reading, AMNART, STROOP, TMT and JLO. Clin Neuropsychol 1996;10:262-278.
21. Tulsky D, Zhu J, Ledbetter M: WAIS-III - WMS-III Technical Manual. San Antonio, The Psychological Corporation, 1997.
22. Hobson V, Hall JR, Harvey M, Cullum CM, Lacritz L, Massman PJ, Waring SC, O'Bryant SE: An examination of the Boston Naming Test: calculation of an 'estimated' 60-item score from 30-and 15-item scores in a cognitively impaired population. Int J Geriatr Psychiatry 2011;26:351-355.
23. Dickstein DL, et al: Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 2010;77:82-102.
24. Piazza F, et al: Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease. Neurobiol Aging 2010, E-pub ahead of print.
25. Okereke OI, et al: A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation. Int J Geriatr Psychiatry 2009;24:177-182.
26. van Oijen M, et al: Plasma Abeta (1-40) and Abeta (1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006;5:655-660.
27. R Development Core Team: R: A language and environment for statistical computing. 2009. www.R-project.org.
28. Breiman L: Random forests. Machine Learn 2001;45:5-32. (Pubitemid 32933532)
29. Graff-Radford NR, et al: Association oflow plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease (erratum appears in Arch Neurol 2007;64:1246). Arch Neurol 2007;64:354-362. (Pubitemid 46425689)
30. Anonymous, Consensus report of the Working Group on: 'Molecular and Biochemical Markers of Alzheimer's Disease'. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group (see comment) (erratum appears in Neurobiol Aging 1998;19:285). Neurobiol Aging 1998;19:109-116.
31. O'Bryant SE, Lucas JA: Estimating the predictive value of the Test of Memory Malingering: an illustrative example for clinicians. Clin Neuropsychol 2006;20:533-540. (Pubitemid 44221705)
32. Vemuri P, et al: Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. NeuroImage 2008;39:1186-1197.
33. Zhang D, et al: Multimodal classification of Alzheimer's disease and mild cognitive impa irment. NeuroImage 2011;55:856-867.
34. Brys M, et al: Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis 2009;16:351-362.
35. O'Bryant SE, et al: Decreased C-reactive protein levels in Alzheimer disease. J Geriatr Psychiatry Neurol 2010;23:49-53.
36. In't Veld BA: Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. New Engl J Med 2001;345:1515-1521. (Pubitemid 33144916)
37. Anthony JC, et al: Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 2000;54:2066-2071. (Pubitemid 30397203)
38. Etminan M, Gill S, Samii A: Effect of nonsteroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003;327:128.
39. Aisen PS, et al: Neither rofecoxib nor naproxen slows cognitive decline in people with mild-to-moderate Alzheimer's disease. Evidence-Based Healthcare 2003;7:200-201. (Pubitemid 38923090)
40. Thal LJ, et al: A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204-1215. (Pubitemid 40720980)
41. Adapt Research Group, et al: Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007;68:1800-1808.